Johnson & Johnson delays Covid-19 vaccine deliveries to Europe

Johnson & Johnson noted in the statement that it would delay the delivery of its vaccine in Europe. This week, the US health ministry asked for a pause on administering the anti-covid drug.

Following the approval given to the J&J’s vaccine in late February, more than 6.8 million doses have already been administered in the US, Prensa Latina reported. According to the FDA, six women between 18 and 48 years of age faced the complications such as rare blood clots within two weeks after being inoculated. One woman died and another one has been hospitalized.

In its efforts to clarify the situation, the pharmaceutical plant released a statement, which says the company has been reviewing these cases with European health authorities. ‘We are aware of an extremely rare disorder involving people with blood clots in combination with low platelets in a small number of individuals who have received our Covid-19 vaccine,’ statement reads.

The top officials from the CDC recommended a pause in the use of J&J’s vaccine out of an abundance of caution. They insisted that people vaccinated with J&J jabs should contact their healthcare provider.